The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10739 malaria professionals are enjoying the free benefits of MalariaWorld today

Covid-19

Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern

June 1, 2020 - 16:00 -- Open Access
Author(s): 
Kamp TJ, Hamdan MH, January CT
Reference: 
J Am Heart Assoc. 2020 May 28:e016887

The SARS‐Cov‐2 viral pandemic causing COVID‐19 disease begs for rapid and innovative treatments. In addition to flu‐like respiratory symptoms, acute cardiac manifestations include cardiac injury, shock and arrhythmia. Several pharmacological therapies have been suggested including repurposing of existing drugs such as chloroquine and hydroxychloroquine, sometimes co‐administered with azithromycin. Chloroquine and hydroxychloroquine were developed in the World War II era for treatment and prophylaxis of malaria, long before modern drug safety surveillance programs.

Potential negative effects of the free use of chloroquine to manage COVID-19 in Colombia

May 27, 2020 - 14:07 -- Open Access
Author(s): 
Teherán AA, Camero G, Hernández C, Perez-Garcia L, Gúzman R, Paniz-Mondolfi A, Ramírez JD
Reference: 
J Med Virol. 2020 May 26

Coronavirus disease 2019 (COVID-19) pandemic has challenged healthcare systems around the world. Unfortunately, failure has ensued: high-income countries have succumbed to the global emergency despite highly prepared human and technological assets. There is no current consensus on pharmacological management of COVID-19, but chloroquine phosphate (CQ) has emerged as a possible therapeutical candidate.

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

May 26, 2020 - 07:51 -- Open Access
Author(s): 
Mehra MR, Desai SS, Ruschitzka F, Patel AN
Reference: 
Lancet. 2020 May 22:S0140-6736(20)31180-6

Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit. Although generally safe when used for approved indications such as autoimmune disease or malaria, the safety and benefit of these treatment regimens are poorly evaluated in COVID-19.

Smooth or Risky Revisit of an Old Malaria Drug for COVID-19

May 19, 2020 - 14:56 -- Open Access
Author(s): 
Pahan P, Pahan K
Reference: 
J Neuroimmune Pharmacol. 2020 May 15

Hydroxychloroquine (HCQ) is an old medication for malaria. In addition to handling this parasitic disease, HCQ is also used to treat a number of autoimmune disorders including rheumatoid arthritis and systemic lupus erythematosus when other medications are not effective. Recently a new viral infection (COVID-19) is rocking the entire world so much that it has already taken more than 200,000 lives throughout the world within the last two months and the World Health Organization was forced to declare it as a pandemic on March 11, 2020.

Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness

April 29, 2020 - 09:52 -- Open Access
Author(s): 
Al-Kofahi M, Jacobson P, Boulware DR, Matas A, Kandaswamy R, Jaber MM, Rajasingham R, Young JH, Nicol MR
Reference: 
Clin Pharmacol Ther. 2020 Apr 28

Hydroxychloroquine is an antimalarial drug being tested as a potential treatment for the novel coronavirus disease 2019 (COVID‐19) pandemic caused by the severe acute respiratory syndrome coronavirus 2( (SARS‐CoV‐2. Although the efficacy of hydroxychloroquine for COVID‐19 remains uncertain, it may serve as a potential prophylactic agent especially in those at high risk, such as healthcare workers, household contacts of infected patients, and the immunocompromised.

COVID-19 and malaria: A symptom screening challenge for malaria endemic countries

April 29, 2020 - 09:50 -- Open Access
Author(s): 
Chanda-Kapata P, Kapata N, Zumla A
Reference: 
Int J Infect Dis. 2020 Apr 25;94:151-153

The unprecedented global coronavirus disease (COVID-19) pandemic caused by SARS-CoV-2 has rapidly spread to all continents (WHO, 2020a). Whilst spread to Africa has been slow, there are now increasing numbers of COVID-19 being reported from African countries who are preparing themselves (Kapata et al., 2020) for an exponential rise in numbers of cases. As of 24th March 2020, there have been 372,757 confirmed COVIDD-19 cases reported to the WHO with 16,231 deaths. In Africa there have been 1305 cases with 25 deaths reported from 33 countries (WHO, 2020b).

Covid-19: Keep essential malaria services going during pandemic, urges WHO

April 27, 2020 - 13:14 -- Open Access
Author(s): 
Thornton J
Reference: 
BMJ. 2020 Apr 23;369:m1637.

Deaths from malaria in sub-Saharan Africa could return to levels last seen 20 years ago because of severe disruptions in access to nets and medicines during the covid-19 pandemic, a new modelling analysis has shown.

Hydroxychloroquine and covid-19

April 20, 2020 - 08:56 -- Open Access
Author(s): 
Sinha N, Balayla G
Reference: 
Postgrad Med J. 2020 Apr 15. pii: postgradmedj-2020-137785

Hydroxychloroquine and chloroquine are medications that have been used for a long time. Their most common use is for the treatment and prophylaxis of malaria. However, these antimalarial drugs are known to also have anti-inflammatory and antiviral effects and are used for several chronic diseases such as systemic lupus erythematosus with low adverse effects.

Pages

Subscribe to RSS - Covid-19